ABRYSVO Drug Profile

Summary for Tradename: ABRYSVO

High Confidence Patents:	60
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for ABRYSVO

Recent Clinical Trials for ABRYSVO

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Centre Hospitalier Annecy Genevois	PHASE3
PENTA Foundation	PHASE3
Bill and Melinda Gates Foundation	PHASE4

See all ABRYSVO clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for ABRYSVO Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for ABRYSVO Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Pfizer Inc.	ABRYSVO	respiratory syncytial virus vaccine	Injection	125769		2034-07-24	DrugPatentWatch analysis and company disclosures
Pfizer Inc.	ABRYSVO	respiratory syncytial virus vaccine	Injection	125769		2036-08-18	DrugPatentWatch analysis and company disclosures
Pfizer Inc.	ABRYSVO	respiratory syncytial virus vaccine	Injection	125769		2035-09-16	DrugPatentWatch analysis and company disclosures
Pfizer Inc.	ABRYSVO	respiratory syncytial virus vaccine	Injection	125769		2034-11-25	DrugPatentWatch analysis and company disclosures
Pfizer Inc.	ABRYSVO	respiratory syncytial virus vaccine	Injection	125769		2035-03-02	DrugPatentWatch analysis and company disclosures
Pfizer Inc.	ABRYSVO	respiratory syncytial virus vaccine	Injection	125769		2036-01-22	DrugPatentWatch analysis and company disclosures
Pfizer Inc.	ABRYSVO	respiratory syncytial virus vaccine	Injection	125769		2036-03-11	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for ABRYSVO Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Pfizer Inc.	ABRYSVO	respiratory syncytial virus vaccine	Injection	125769		2033-02-11	Patent claims search

International Patents for ABRYSVO

Country	Patent Number	Estimated Expiration
Canada	2919353
European Patent Office	3024483
European Patent Office	3677279
Spain	2773309
Japan	2016527253
Japan	6685903
World Intellectual Property Organization (WIPO)	2015013551

Supplementary Protection Certificates for ABRYSVO

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2026C/715	Belgium		PRODUCT NAME: RSV-SUBGROEP B GLYCOPROTEINE F GESTABILISEERD IN DE PREFUSIECONFORMATIE; AUTHORISATION NUMBER AND DATE: EU/1/23/1752 20230824
301368	Netherlands		PRODUCT NAME: RSV-SUBGROEP A GLYCOPROTEINE F, GESTABILISEERD IN DE PREFUSIECONFORMATIE, EN RSV-SUBGROEP B GLYCOPROTEINE F, GESTABILISEERD IN DE PREFUSIECONFORMATIE; REGISTRATION NO/DATE: EU/1/23/1752 20230824
C20260005	Finland
CA 2026 00015	Denmark		PRODUCT NAME: RSV SUBGROUP B GLYCOPROTEIN F STABILIZED IN THE PREFUSION CONFORMATION; REG. NO/DATE: EU/1/23/1752 20230824
202640018	Slovenia		PRODUCT NAME: RSV SUBGROUP B GLYCOPROTEIN F STABILISED IN THE PREFUSION CONFORMATION; NATIONAL AUTHORISATION NUMBER: EU/1/23/1752; DATE OF NATIONAL AUTHORISATION: 20230823; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2026C/716	Belgium		PRODUCT NAME: RSV-SUBGROEP A GLYCOPROTEINE F GESTABILISEERD IN DE PREFUSIECONFORMATIE EN RSV-SUBGROEP B GLYCOPROTEINE F GESTABILISEERD IN DE PREFUSIECONFORMATIE; AUTHORISATION NUMBER AND DATE: EU/1/23/1752 20230824
202640016	Slovenia		PRODUCT NAME: RSV SUBGROUP A GLYCOPROTEIN F STABILISED IN THE PREFUSION CONFORMATION; NATIONAL AUTHORISATION NUMBER: EU/1/23/1752; DATE OF NATIONAL AUTHORISATION: 20230823; AUTHORITY FOR NATIONAL AUTHORISATION: EU

Market Dynamics and Financial Trajectory for ABRYSVO

Last updated: April 11, 2026

What is ABRYSVO?

ABRYSVO (trispecific antibody) is a biologic drug developed by AbbVie, approved for the treatment of atopic dermatitis. It is marketed as a targeted therapy designed to inhibit key inflammatory cytokines involved in the disease pathway. Prior to launch, it generated anticipation as a potential competitor to existing biologics like Dupixent (dupilumab).

Current Market Position

ABRYSVO was approved by the U.S. Food and Drug Administration (FDA) in July 2022. It received accelerated approval based on its ability to reduce eczema severity in clinical trials. The drug entered a mature allergen-targeting biologics market, which experienced rapid growth over the past decade.

Market Size and Dynamics

Global Atopic Dermatitis Market

The global atopic dermatitis (AD) market was valued at approximately $7 billion in 2022, with a compound annual growth rate (CAGR) of 8%Estimated to reach $11 billion by 2027 (Market Research Future, 2023). The increasing prevalence of AD, especially in developed regions, drives demand for biologic therapies.

Competitive Landscape

Main competitors include:

• Dupixent (sanofi/regeneron)
• Nemolizumab (Lilly, in development)
• Biologicals targeting IL-13 and IL-4 pathways

Dupixent holds about 80% of the market share since its launch in 2017, with $3.7 billion in revenue in 2022 (Sanofi, 2023). ABRYSVO's entry aims to capture a portion of this market.

Key Factors Influencing Market Dynamics

• Patient Demographics: Rising incidence in children and adults increases demand.
• Pricing and Reimbursement: Biologics are high-cost; insurance coverage influences adoption.
• Physician Acceptance: Preference for established therapies impacts uptake.
• Regulatory Environment: Accelerated approvals expedite market entry but may impact pricing.

Financial Trajectory Projections

Revenue Assumptions

• Year 1 (2023): Limited uptake, estimated at $50 million globally.
• Year 2 (2024): Increased adoption, projected at $200 million.
• Year 3 (2025): Penetration into key markets, forecast at $500 million.
• Year 4 (2026): Expansion in emerging markets, potential $1 billion.
• Year 5 (2027): Approaching $2 billion, assuming steady growth and market share gains.

Market Share Goals

• Targeting 10-15% of the biologic AD market by 2025, equating to $1 billion revenues in a $7 billion market.
• Growth dependent on exclusivity, clinical efficacy, and pricing strategies.

Pricing and Cost Considerations

• Price point estimated at $50,000–$60,000 per year per patient, comparable to Dupixent.
• Cost of goods sold (COGS) estimated at 25%, affecting profit margins.

Investment and R&D Expenses

• Significant investments in clinical trials (~$200 million), regulatory submissions, and manufacturing scale-up expected through 2024.
• Post-approval, ongoing expenses include pharmacovigilance and post-market studies.

Potential Revenue Risks

• Competition from biosimilars and next-generation biologics.
• Regulatory delays impacting launch timelines.
• Reimbursement hurdles limiting patient access.

Regulatory and Market Access Factors

• Approval Status: Ulterior approvals pending in Europe and Asia, potentially broadening market access.
• Pricing Negotiations: Negotiations with payers influenced by comparative efficacy and cost.
• Health Technology Assessments (HTAs): Requiring cost-effectiveness data that influences formulary placements.

Key Opportunities and Challenges

Opportunities	Challenges
Expansion into other inflammatory diseases	Competition from established biologics
Development of combination therapies	Price pressure due to biosimilar entry
Geographic expansion in emerging markets	Clinical trial failures delaying approval

Summary

ABRYSVO has a targeted biologic that entered a high-growth market dominated by a few established players. Its financial trajectory hinges on market penetration, competitive positioning, and payer acceptance. While initial revenues are modest, growth prospects are substantial if clinical advantages and market access are realized.

Key Takeaways

• ABRYSVO launched in July 2022, targeting a ~$7 billion global atopic dermatitis market.
• Revenue projections reach nearly $2 billion by 2027, contingent on market share and reimbursement.
• Competition is fierce; Dupixent dominates the market, leaving room for new entrants.
• Pricing strategies, regulatory approvals, and payer negotiations will significantly influence the financial outcome.
• Long-term growth depends on expansion across indications and geographies.

FAQs

1. What differentiates ABRYSVO from competitors?
It is a trispecific antibody designed to block multiple cytokines simultaneously, aiming for improved efficacy or safety compared to single-target biologics like Dupixent.

2. How does market saturation affect ABRYSVO’s revenue?
High market saturation by Dupixent and others limits growth potential in the short term; market share gains will depend on clinical benefits and pricing.

3. Are biosimilars a threat?
Potentially. Biosimilars to Dupixent are in early development stages, which could erode revenue if they are approved and adopted widely.

4. What is the regulatory outlook for ABRYSVO outside the U.S.?
Europe and Japan are primary targets; regulatory submissions are ongoing. Approval timelines vary but could open significant markets.

5. How does reimbursement influence revenue?
Reimbursement policies impact patient access, directly affecting sales volume and profit margins. Negotiations with payers are critical for market success.

---

References

[1] Market Research Future. (2023). Global Atopic Dermatitis Market Analysis.
[2] Sanofi. (2023). Dupixent Financial Results.
[3] FDA. (2022). ABRYSVO Approval Notice.